CNAT - コナタス・ファ―マシュ―ティカルズ (Conatus Pharmaceuticals Inc.) コナタス・ファ―マシュ―ティカルズ



symbol CNAT
会社名 Conatus Pharmaceuticals Inc (コナタス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 コナトゥス・ファーマシューティカルズ(Conatus Pharmaceuticals Inc.)はバイオテクノロジー企業である。同社は肝疾患を治療する医薬品の開発・商用化に従事する。同社は薬剤の開発・商用化事業を運営する。同社は慢性肝疾患患者の治療用口腔活性汎カスパーゼプロテアーゼ阻害剤であるemricasanの開発に従事する。Emricasanは肝疾患の進行を中断させ、肝疾患の複数の領域で治療法を提供する。Emricasanは線維症と肝硬変によって引き起こされる慢性肝疾患の進行を停止させるように設計される。Emricasanは、アポトーシスおよび炎症をもたらす機能を含む細胞機能のモジュレーターとして機能する関連酵素ファミリーであるカスパーゼを阻害することによって作用する。   コナタス・ファ―マシュ―ティカルズは開発段階にある米国のバイオテクノロジ―企業。肝臓疾患の新薬に開発と商業化に従事する。慢性肝疾患、慢性肝疾患急性増悪期、C型肝炎による同所性肝移植、非アルコ―ル性脂肪性肝炎などの治療薬として、リ―ド化合物であるエムリカサンを開発中。   Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA.
本社所在地 16745 West Bernardo Dr. Suite 200 San Diego CA 92127 USA
代表者氏名 David F. Hale デイヴィッドF.ヘイル
代表者役職名 Independent Chairman of the Board
電話番号 +1 858-376-2600
設立年月日 38534
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 28人
EBITDA EBITDA(百万ドル) -17.96156
終値(lastsale) 4.83
時価総額(marketcap) 145726161.84
時価総額 時価総額(百万ドル) 149.64840
売上高 売上高(百万ドル) 36.88129
企業価値(EV) 企業価値(EV)(百万ドル) 105.46040
当期純利益 当期純利益(百万ドル) -17.87178
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Conatus Pharmaceuticals Inc revenues increased 9% to $18.5M. Net loss increased 5% to $9.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 8% to $22.8M (expense) General and administrative increase of 7% to $5.3M (expense).



   The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas  2020/05/27 11:25:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE )(announced positive one-year Phase 1/2 study and Phase 2 open-label extension study of pegzilarginase in Arginase 1 Deficiency patients) Allogene Therapeutics Inc (NASDAQ: ALLO ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX )( announced positive top-line data from a late-stage study of efgartigimod in patients with generalized Myasthenia Gravis) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )(gained on sell-side comment on the company being a potential target for Sanofi SA (NASDAQ: SNY ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Catalent Inc (NYSE: CTLT ) ChemoCentryx Inc (NASDAQ: CCXI ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cue Biopharma Inc (NASDAQ: CUE ) Evoke Pharma Inc (NASDAQ: EVOK ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   Is Conatus Pharmaceuticals Inc.'s (NASDAQ:CNAT) CEO Paid Enough Relative To Peers?  2019/11/03 13:22:39 ACI Information Group
In 2005 Steven Mento was appointed CEO of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). First, this article will compare…
   Caspase 3 Market Comprehensive Study by Leading Players- Aptose Biosciences, BeyondSpring Pharmaceuticals, Conatus Pharmaceuticals  2019/11/02 09:57:00 MarketWatch
Nov 02, 2019 (HTF Market Intelligence via COMTEX) -- An extensive analysis of the Global Caspase 3 market strategy of the leading companies in the precision…
   Conatus (CNAT) Upgraded to Strong Buy: Here's What You Should Know  2019/08/19 13:00:08 Zacks Investment Research
Conatus (CNAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
   Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies  2019/08/07 10:00:00 Zacks Investment Research
Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コナタス・ファ―マシュ―ティカルズ CNAT Conatus Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)